Company page

Neurogene Inc.

Neurogene Inc. is a public biotechnology company traded under the ticker NGNE on the American market. The company focuses on developing innovative gene therapies for rare genetic diseases. With a market cap of approximately $695 million, Neurogene is positioned to advance its research and development initiatives in the biotech sector.